A Randomized Control Trial of Intracoronary Reopro to Improve Coronary Microvascular Function

NCT02105870 NA UNKNOWN

Microvascular dysfunction is a key determinant of pathogenesis and outcome in patients suffering an acute myocardial infarction. The investigators hypothesise that treatment with intracoronary abciximab, a potent anti platelet agent, at the time of coronary stent insertion, will improve microvascular function.

Details

Lead sponsor	University of Melbourne
Phase	NA
Status	UNKNOWN
Enrolment	40
Start date	2012-02
Completion	2014-06

Conditions

• Myocardial Infarction
• Coronary Artery Disease

Interventions

• Abciximab

Primary outcomes

• Index of Microvascular Resistance — within 3 hours
  We will assess IMR in the catheterisation laboratory immediately before PCI, then intracoronary reopro or placebo will be administered and we will re-assess IMR 15 minutes post delivery of the study drug. Finally we will perform PCI and immediately measure IMR post-procedure.

Countries

Australia